Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Risedronic Acid × Thoracic × Clear all
NCT03861091 2023-07-27

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

Wake Forest University Health Sciences

Phase 2 Completed
84 enrolled 13 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡